主页 > 医药科学 >
【medical-news】缓释托吡酯帮助糖尿病患者减轻体
NEW YORK (Reuters Health) Jun 15 - A controlled release formulation of topiramate is effective adjunctive therapy for weight loss in obese type 2 diabetics treated with diet and exercise alone or in combination with metformin, researchers report in the June issue of Diabetes Care. However, the new formulation appears to do little to curb psychiatric and other adverse effects of topiramate.
Dr. Julio Rosenstock of Dallas Diabetes and Endocrine Center, Texas and colleagues note that topiramate is used in many countries for the treatment of seizure disorders and the prophylaxis of migraines. The agent is also known to induce significant weight loss.
The controlled release formulation was developed to allow once-daily dosing and to improve tolerability. To assess the effectiveness of this approach in weight loss, the researchers conducted a randomized placebo-controlled trial in overweight or obese diabetics.
In the 111 patients whose results were analyzed following 16 weeks of treatment, the topiramate group lost 6.0 kg, 5.8% of their baseline body weight. The corresponding figures in the placebo group were 2.5 kg and 2.3%.
In the topiramate group, hemoglobin A1C improved from 7.6% to 6.7%, significantly better than the drop from 7.4% to 7.1% seen in the placebo group. Topiramate also significantly reduced blood pressure and urinary albumin excretion.
However, the researchers note that there were substantially more CNS and psychiatric adverse events in patients treated with topiramate. Such findings were similar to those previously reported.
For example, 43% of topiramate patients experienced central and peripheral nervous system disorders, compared to 21% of placebo patients. For psychiatric disorders, the figures were 33% and 11%.
These results, the investigators say, "indicate that a controlled-release formulation does not provide tolerability advantages over immediate-release formulation."
The propensity to provoke such adverse events, the team concludes, "makes it unsuitable for the treatment of obesity and diabetes."
Diabetes Care 2007;30:1480-1486.
http://www.medscape.com/viewarticle/558349 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Slow Release Topiramate Helps Diabetics Lose Weight
缓释托吡酯帮助糖尿病患者减轻体重
NEW YORK (Reuters Health) Jun 15 - A controlled release formulation of topiramate is effective adjunctive therapy for weight loss in obese type 2 diabetics treated with diet and exercise alone or in combination with metformin, researchers report in the June issue of Diabetes Care. However, the new formulation appears to do little to curb psychiatric and other adverse effects of topiramate.
纽约（路透社健康新闻部）6月15日—研究人员在6月份出版的《糖尿病治疗》杂志上撰文指出，对于接受饮食和锻炼单独治疗或合并二甲双胍治疗的2型糖尿病患者，托吡酯控释制剂可作为降低体重的有效辅助治疗。然而，该新制剂似乎并不能减少托吡酯精神和其它方面的副作用。
Dr. Julio Rosenstock of Dallas Diabetes and Endocrine Center, Texas and colleagues note that topiramate is used in many countries for the treatment of seizure disorders and the prophylaxis of migraines. The agent is also known to induce significant weight loss.
德州达拉斯糖尿病和内分泌中心的Julio Rosenstock医生及其同事指出，托吡酯在许多国家用于治疗癫痫和预防偏头痛，它还可显著降低体重。
The controlled release formulation was developed to allow once-daily dosing and to improve tolerability. To assess the effectiveness of this approach in weight loss, the researchers conducted a randomized placebo-controlled trial in overweight or obese diabetics.
开发托吡酯控释制剂，以便每日服药一次和改善耐受性。研究人员对超重或肥胖糖尿病患者进行了一项随机、安慰剂对照试验，以评价该制剂的降低体重的作用。
In the 111 patients whose results were analyzed following 16 weeks of treatment, the topiramate group lost 6.0 kg, 5.8% of their baseline body weight. The corresponding figures in the placebo group were 2.5 kg and 2.3%.
111名患者参与了为期16周的治疗，结果分析表明，托吡酯组体重减少6.0kg，为基线体重的5.8%；而安慰剂组相应数据分别是2.5kg和 2。3%.
In the topiramate group, hemoglobin A1C improved from 7.6% to 6.7%, significantly better than the drop from 7.4% to 7.1% seen in the placebo group. Topiramate also significantly reduced blood pressure and urinary albumin excretion.
托吡酯组糖化血红蛋白A1C水平也得以改善（从7.6%降至6.7%），明显好于安慰剂组（从7.4%降至7.1%）。托吡酯还显著降低血压和尿蛋白排泄。
However, the researchers note that there were substantially more CNS and psychiatric adverse events in patients treated with topiramate. Such findings were similar to those previously reported.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-12 23:53
医学,生命科学网